Finafloxacin is a new generation, safe fluoroquinolone with very unique properties. The drug is highly active against a broad spectrum of pathogens and is ideally suited for the treatment of serious infections requiring hospitalization, like urinary tract infections. Finafloxacin has also shown in different animal models strong activity against several bacteria classified by the US CDC (Centers for Disease Control and Prevention) as category A and B biothreat pathogens. Furthermore, the otic suspension of finafloxacin (Xtoro™) has already received market approval by the US FDA and Health Canada.